{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:54Z","timestamp":1761057954247,"version":"build-2065373602"},"reference-count":17,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4763,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,1,2]]},"abstract":"<jats:p>Hyperglycemia is an adverse effect that occurs with all protease inhibitors, although few cases have been reported in the literature. Most patients with human immunodeficiency virus infection receiving antiretroviral therapy are also taking at least one protease inhibitor. Patients with a family history of diabetes mellitus may be at a greater risk of developing this adverse effect. It is therefore prudent to monitor all patients starting protease inhibitor therapy for the onset of diabetes or hyperglycemia, particularly those with a family history of diabetes. Baseline fasting plasma glucose or serum glucose level should be measured with follow\u2010up measurements every 3 months for approximately 6\u201312 months.<\/jats:p>","DOI":"10.1592\/phco.19.1.114.30514","type":"journal-article","created":{"date-parts":[[2004,4,26]],"date-time":"2004-04-26T05:49:43Z","timestamp":1082958583000},"page":"114-117","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A Review of Protease Inhibitor\u2010Induced Hyperglycemia"],"prefix":"10.1002","volume":"19","author":[{"given":"Michele B.","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Creuza","family":"Simionatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"50","article-title":"Treating HIV with protease inhibitors","author":"Petroski N.A.","year":"1996","journal-title":"Am Druggist"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1001\/jama.1997.03540480062040","article-title":"Antiretroviral therapy for HIV Infection in 1997. Updated recommendations of the International AIDS Society\u2014USA panel","volume":"277","author":"Carpenter C.C.J.","year":"1997","journal-title":"JAMA"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.278.5.379"},{"issue":"1","key":"e_1_2_1_5_2","first-page":"25","article-title":"Protease inhibitor side effects take people by surprise","volume":"12","author":"Huff A.","year":"1997","journal-title":"GMHC Treatment Issues Newsletter of Experimental AIDS Therapies"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63513-1"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00017"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00016"},{"volume-title":"Drug evaluations [monograph on CD\u2010ROM]","year":"1998","author":"Micromedex, Inc.","key":"e_1_2_1_9_2"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199801010-00007"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-7-199304010-00008"},{"key":"e_1_2_1_12_2","first-page":"1465","volume-title":"Goodman and Gilman's the pharmacologic basis of therapeutics","author":"Kahn C.R.","year":"1990"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"volume-title":"Norvir package insert","year":"1996","author":"Abbott Laboratories.","key":"e_1_2_1_14_2"},{"volume-title":"Fortovase package insert","year":"1997","author":"Roche Laboratories.","key":"e_1_2_1_15_2"},{"volume-title":"Crixivan package insert","year":"1996","author":"Merck & Co.","key":"e_1_2_1_16_2"},{"volume-title":"Viracept package insert","year":"1997","author":"Agouron Pharmaceuticals.","key":"e_1_2_1_17_2"},{"volume-title":"Drug facts and comparisons","year":"1998","key":"e_1_2_1_18_2"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.1.114.30514","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.1.114.30514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:36Z","timestamp":1761041916000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.1.114.30514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1,2]]}},"alternative-id":["10.1592\/phco.19.1.114.30514"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.1.114.30514","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1999,1,2]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}